Jasper Therapeutics completes acquisition of Kira Pharmaceuticals in all-stock deal
JSPR•Pipeline and cash runway
Kira out-licensed KP-301 and KP-402 to Mirador Therapeutics for a $12 million upfront payment, with additional milestones possible.
Pro forma cash at closing, including the financing and out-licensing proceeds, is expected to fund operations into the second half of 2028.
Shares will continue trading on Nasdaq under the ticker JSPR, with focus on KP-104, briquilimab, and KP-701 development.
Acquisition and financing completed
Jasper Therapeutics completed an all-stock acquisition of complement-therapy developer Kira Pharmaceuticals, forming a combined immunology-focused drug developer.
The deal was paired with a private placement of non-voting convertible preferred stock expected to raise about $132 million gross.
